Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies
- PMID: 20431083
- DOI: 10.1161/STROKEAHA.109.572594
Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies
Abstract
Background and purpose: Cerebral microbleeds (MB) are potential risk factors for intracerebral hemorrhage (ICH), but it is unclear if they are a contraindication to using antithrombotic drugs. Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke (IS)/transient ischemic attack (TIA).
Methods: We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use. We also analyzed published and unpublished follow-up data to determine the risk of ICH in antithrombotic users with MB.
Results: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01). There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01). There was a smaller excess of MB in antiplatelet users vs nonusers with ICH (OR, 1.7; 95% CI, 1.3-2.3; P<0.001), but findings were similar for antiplatelet users with IS/TIA (OR, 1.4; 95% CI, 1.2-1.7; P<0.001; P difference=0.25). In pooled follow-up data for 768 antithrombotic users, presence of MB at baseline was associated with a substantially increased risk of subsequent ICH (OR, 12.1; 95% CI, 3.4-42.5; P<0.001).
Conclusions: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH. Limited prospective data corroborate these findings, but larger prospective studies are urgently required.
Similar articles
-
Antithrombotic treatment after stroke due to intracerebral haemorrhage.Cochrane Database Syst Rev. 2023 Jan 26;1(1):CD012144. doi: 10.1002/14651858.CD012144.pub3. Cochrane Database Syst Rev. 2023. PMID: 36700520 Free PMC article.
-
Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage.Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD005951. doi: 10.1002/14651858.CD005951.pub5. Cochrane Database Syst Rev. 2023. PMID: 37870112 Free PMC article.
-
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.Cochrane Database Syst Rev. 2022 Jul 14;7(7):CD012269. doi: 10.1002/14651858.CD012269.pub2. Cochrane Database Syst Rev. 2022. PMID: 35833913 Free PMC article.
-
Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.Cochrane Database Syst Rev. 2001;(4):CD001342. doi: 10.1002/14651858.CD001342. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001342. doi: 10.1002/14651858.CD001342.pub2. PMID: 11687110 Updated.
-
Quantity of Cerebral Microbleeds, Antiplatelet Therapy, and Intracerebral Hemorrhage Outcomes: A Systematic Review and Meta-analysis.J Stroke Cerebrovasc Dis. 2015 Dec;24(12):2728-37. doi: 10.1016/j.jstrokecerebrovasdis.2015.08.003. Epub 2015 Sep 3. J Stroke Cerebrovasc Dis. 2015. PMID: 26342996
Cited by
-
The Rotterdam Study: 2014 objectives and design update.Eur J Epidemiol. 2013 Nov;28(11):889-926. doi: 10.1007/s10654-013-9866-z. Epub 2013 Nov 21. Eur J Epidemiol. 2013. PMID: 24258680
-
Cystatin C, a novel indicator of renal function, reflects severity of cerebral microbleeds.BMC Neurol. 2014 Jun 12;14:127. doi: 10.1186/1471-2377-14-127. BMC Neurol. 2014. PMID: 24925313 Free PMC article.
-
Background and distribution of lobar microbleeds in cognitive dysfunction.Brain Behav. 2017 Oct 16;7(11):e00856. doi: 10.1002/brb3.856. eCollection 2017 Nov. Brain Behav. 2017. PMID: 29201555 Free PMC article.
-
Use of anticoagulant therapy and cerebral microbleeds: a systematic review and meta-analysis.J Neurol. 2021 May;268(5):1666-1679. doi: 10.1007/s00415-019-09572-x. Epub 2019 Oct 15. J Neurol. 2021. PMID: 31616992
-
Risk of long-term anticoagulation under sustained severe arterial hypertension: A translational study comparing warfarin and the new oral anticoagulant apixaban.J Cereb Blood Flow Metab. 2017 Mar;37(3):855-865. doi: 10.1177/0271678X16642443. Epub 2016 Jul 20. J Cereb Blood Flow Metab. 2017. PMID: 27189904 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous